Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents including thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome. It is grouped under the following drug class(es): Alpha-2 agonists. Its therapeutic use is listed as antihypertensives and cardiovascular. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Norcynt, Nucynt, Cynt, Normatens and Fisiotens. Its PubChem CID is 4810.
Moxonidine
| CAS No | 75438-57-2 |
|---|---|
| Molecular Formula | C9H12ClN5O |
| Molecular Weight | 241.68 g/mol |
| Synonyms | 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents including thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive.
The listed CAS number is 75438-57-2.
The listed molecular formula is C9H12ClN5O.
The listed molecular weight is 241.68 g/mol.
4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine.
The source lists Norcynt, Nucynt, Cynt, Normatens and Fisiotens.